Commonwealth Equity Services’s VistaGen Therapeutics VTGN Stock Holding History

Commonwealth Equity Services’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-670	Closed	-$2	–	3933
2023 Q1	$2	Buy	670 +33	+5%	+$173	﹤0.01%	3767
2022 Q4	$1K	Sell	637 -333	-34%	-$1.25K	﹤0.01%	3699
2022 Q3	$4K	Buy	970 +255	+36%	+$2.53K	﹤0.01%	3646
2022 Q2	$18K	Buy	715 +25	+4%	+$883	﹤0.01%	3579
2022 Q1	$25K	Hold	690	–	–	﹤0.01%	3641
2021 Q4	$40K	Sell	690 -95	-12%	-$6.18K	﹤0.01%	3556
2021 Q3	$64K	Hold	785	–	–	﹤0.01%	3477
2021 Q2	$74K	Buy	785 +178	+29%	+$13.2K	﹤0.01%	3436
2021 Q1	$38K	Buy	+607	New	+$40.5K	﹤0.01%	3353
2020 Q4	–	Sell	-440	Closed	-$9K	–	3270
2020 Q3	$9K	Hold	440	–	–	﹤0.01%	3036
2020 Q2	$6K	Hold	440	–	–	﹤0.01%	2947
2020 Q1	$5K	Hold	440	–	–	﹤0.01%	2804
2019 Q4	$9K	Hold	440	–	–	﹤0.01%	2873
2019 Q3	$14K	Buy	+440	New	+$9.81K	﹤0.01%	2810

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services's VTGN Position: Q2 2023 in Review

Commonwealth Equity Services sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 670 shares — an estimated $2 sold.

Commonwealth Equity Services first reported a position in VTGN in Q3 2019 and held it in 14 quarters. The position peaked at $74K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

Commonwealth Equity Services reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
Commonwealth Equity Services sold 670 VistaGen Therapeutics shares in Q2 2023, an estimated $2.
Commonwealth Equity Services first reported a position in VistaGen Therapeutics in Q3 2019 and held it in 14 quarters.
Commonwealth Equity Services's VistaGen Therapeutics position peaked at $74K in Q2 2021.
33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Commonwealth Equity Services's 13F filing for Q2 2023, filed 10 Aug 2023.